Piper Jaffray Upgrades Sarepta Therapeutic (SRPT) to Overweight
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Piper Jaffray upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Overweight with a price target of $64.00 (from $17.00).
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Raises Price Target on ManpowerGroup (MAN) Following 3Q Surprise
- Seaport Global Securities Upgrades Tutor Perini Corporation (TPC) to Buy
- Susquehanna Cuts Price Target on KLA-Tencor (KLAC) Following Strong 1Q
Create E-mail Alert Related CategoriesAnalyst PT Change, Upgrades
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!